Diabetic neuropathy

Handbook of Clinical Neurology

Volumn 120, Issue , 2014, Pages 773-785

  Charnogursky, Gerald ^a   Lee, Hong ^a   Lopez, Norma ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Autonomic neuropathy; Diabetic complications; Mononeuropathy; Peripheral neuropathy; Polyneuropathy

Indexed keywords

ARTICLE; AUTONOMIC NEUROPATHY; DIABETIC COMPLICATIONS; DIABETIC NEUROPATHY; HUMAN; MONONEUROPATHY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; RISK FACTOR;

AUTONOMIC NEUROPATHY; DIABETIC COMPLICATIONS; MONONEUROPATHY; PERIPHERAL NEUROPATHY; POLYNEUROPATHY;

DIABETIC NEUROPATHIES; HUMANS; RISK FACTORS;

EID: 84890838122     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-7020-4087-0.00051-6     Document Type: Chapter

References (98)

1. Albers J., Herman W., Pop-Busai R., et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Diabetes Care 2010, 33:1090-1096.
2. Backonja M., Glanzman R. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003, 25:81-104.
3. Backonja M., Beydoun A., Edwards K., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998, 280:1831-1836.
4. Backonja M., Wallace M., Blonsky E., et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of post herpetic neuralgia: a randomized, double-blind study. Lancet Neurol 2008, 7:1102-1112.
5. Barohn R., Sahenk Z., Warmolts J., et al. The Bruns-Garland syndrome (diabetic amyotrophy). Revisited 100 years later. Arch Neurol 1991, 48(11):1130-1135.
6. Boulton A., Malik R., Arezzo J., et al. Diabetic somatic neuropathies. Diabetes Care 2004, 27:1458-1486.
7. Boulton A., Vinik A., Arezzo J., et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962.
8. Bril V., Hirose T., Tomioka S., et al. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009, 32:1256-1260.
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
10. Brussee V., Cunningham F., Zochodne D. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 2004, 53:1824-1830.
11. Cameron N., Cotter M. Effects of protein kinase C beta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid metabolism. Diabetes Metab Res Rev 2002, 18:315-323.
12. Chen H., Hwu C., Kuo B., et al. Abnormal cardiovascular reflex tests are predictors of mortality in type 2 diabetes mellitus. Diabet Med 2001, 18:268-273.
13. Cohen J., Jeffers B., Faldut D., et al. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). Muscle Nerve 1998, 21:72-80.
14. Diabetes Control and Complications Trial Research Group The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995, 122:561-568.
15. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
16. Dyck P., Kratz K., Lehman K., et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991, 41:799-807.
17. Dyck P., Karnes J., O'Brien P., et al. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992, 42:1164-1170.
18. Dyck P., Kratz K., Karnes J., et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993, 43:817-824.
19. Dyck P., Dyck P., Klein C., et al. Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population-based study. Muscle Nerve 2007, 36:536-541.
20. England J., Gronseth G., Franklin G., et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review): report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009, 72:185-192.
21. Ewing D., Boland O., Neilson J., et al. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991, 34:182-185.
22. Feldman E., Stevens M., Thomas P., et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994, 17:1281-1289.
23. Freeman R., Durso-DeCruz E., Emir B. Efficiacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy. Diabetes Care 2008, 31:1448-1454.
24. Gaede P., Lund-Andersen H., Parving H., et al. Effect of a multifactoral intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
25. Galer B., Gianas A., Jensen M. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000, 47:123-128.
26. Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 2006, 12(Suppl 1):34-41.
27. Gilden D.H. Clinical practice. Bell's palsy. N Engl J Med 2004, 351:1323-1331.
28. Gulliford M., Latinovic R., Charlton J., et al. Increased incidence of carpal tunnel syndrome up to 10 years before diagnosis of diabetes. Diabetes Care 2006, 29:1929-1930.
29. Hamman R., Franklin G., Mayer E., et al. Microvascular complications of NIDDM in Hispanics and non-Hispanic whites. San Luis Valley Diabetes Study. Diabetes Care 1991, 14:655-664.
30. Hoeldtke R., Streeten D. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 1993, 329:611-615.
31. Ishii H., Koya D., King G. Proteins kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med (Berl) 1998, 76:21-31.
32. Janssens J., Peeters T., Vantrappen G., et al. Improvement of gastric emptyingin diabetic gastroparesis by erythromycin. N Engl J Med 1990, 32:1028-1031.
33. Jermendy G., Toth L., Voros P., et al. Cardiac autonomic neuropathy and QT interval length. A follow-up study in diabetic patients. Acta Cardiol 1991, 46:189-200.
34. Kajdasz D., Iyengar S., Desaiah D., et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007, 29:2536-2546.
35. Kennedy J., Zochodne D. The regenerative deficit of peripheral nerves in experimental diabetes: its extent, timing and possible mechanisms. Brain 2000, 123:2118-2129.
36. Kennedy J., Zochodne D.W. Impaired peripheral nerve regeneration in diabetes mellitus. J Peripher Nerv Syst 2005, 10:144-157.
37. Kennedy W., Navarro X., Sutherland D. Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology 1995, 45:773-780.
38. Kikta D.G., Breuer A.C., Wilbourn A.J. Thoracic root pain in diabetes: the spectrum of clinical and electromyographic findings. Ann Neurol 1982, 11:80-85.
39. Kincaid J., Price K., Jimenez M., et al. Correlation of vibratory quantitative sensory testing and nerve conduction studies in patients with diabetes. Muscle Nerve 2007, 36:821-827.
40. Liatis S., Marinou K., Tentolouris N., et al. Usefulness of a new indicator test for the diagnosis of peripheral and autonomic neuropathy in patients with diabetes mellitus. Diabet Med 2007, 24:1375-1380.
41. Low P., Nickander K., Tritcshler H. The role of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997, 46:S38-S42.
42. Low P., Gilden J., Freeman R., et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. JAMA 1997, 277:1046-1051.
43. Maganti K., Onyemere K., Jones M. Oral erythromycin and symptomatic relief in gastroparesis: a systematic review. Am J Gastroenterol 2003, 98:259-263.
44. Martin C., Albers J., Herman W., et al. The DCCT/EDIC research group. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006, 29:340-344.
45. Maser R., Pfeifer M., Dorman J., et al. Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of Diabetes Complications Study III. Arch Intern Med 1990, 150:1218-1222.
46. Mehra S., Tavakoli M., Kallinikos P., et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care 2007, 30:2608-2612.
47. Navarro X., Kennedy W., Aeppli D., et al. Neuropathy and mortality in diabetes: influence of pancreas transplantation. Muscle Nerve 1996, 19:1009-1016.
48. Negrin P., Zara G. Conduction studies as prognostic parameters in the natural history of diabetic neuropathy: a long-term follow-up of 114 patients. Electromyogr Clin Neurophysiol 1995, 35:341-350.
49. Newrick P., Wilson A., Jakubowski J., et al. Sural nerve oxygen tension in diabetes. Br Med J (Clin Res Ed) 1986, 293:1053-1054.
50. Niakan E., Harati Y., Rolak L., et al. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med 1986, 146:2229-2230.
51. O'Brien I.A., McFadden J.P., Corrall R.J. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991, 79:495-502.
52. Onde M., Ozge A., Senol M., et al. The sensitivity of clinical diagnostic methods in the diagnosis of diabetic neuropathy. J Int Med Res 2008, 36:63-70.
53. Orchard T., Lloyd C., Maser R., et al. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Res Clin Pract 1996, 34(Suppl):S165-S171.
54. Oyer D., Saxon D., Shah A. Quantitative assessment of diabetic peripheral neuropathy with use of the clanging tuning fork test. Endocr Pract 2007, 13:5-10.
55. Pacher P., Obrosova I., Mabley J., et al. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 2005, 12:267-275.
56. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
57. Pecket P., Schattner A. Concurrent Bell's palsy and diabetes mellitus: a diabetic mononeuropathy?. J Neurol Neurosurg Psychiatry 1982, 45:652-655.
58. Quattrini C., Jeziorska M., Boulton A., et al. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy. Diabetes Care 2008, 31:140-145.
59. Rathmann W., Ziegler D., Jahnke M., et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993, 10:820-824.
60. Reljanovic M., Reichel G., Rett K., et al. Treatment of diabetic polyneuropathy with antioxidant thioctic acid (α-lipoic acid): a two-year multi-center randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999, 31:171-179.
61. Ropper A., Gorson K., Gooch C., et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol 2009, 65:386-393.
62. Rowbotham M., Goli V., Kunz N., et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo- controlled study. Pain 2004, 110:697-706.
63. Sampson M., Wilson S., Karagiannis P., et al. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q J Med 1990, 75:635-646.
64. Sandercock D., Cramer M., Wu J., et al. Gabapentin extended release for the treatment of painful diabetic neuropathy. Diabetes Care 2009, 32:e20.
65. Shibao C., Okamoto L., Gamboa A., et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2010, 56:847.
66. Singer W., Sandroni P., Opfer-Gehrking T., et al. Pyridostigmine treatment trial in heneurogenic orthostatic hypotension. Arch Neurol 2006, 63:513.
67. Singh R., Barden A., Mori T., et al. Advanced glycation end products: a review. Diabetologia 2001, 44:129-146.
68. Singleton J., Smith A. Neuropathy associated with prediabetes: what is new in 2007?. Curr Diab Rep 2007, 7:420-424.
69. Spallone V., Maiello M., Cicconetti E., et al. Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non insulin-dependent diabetes. Diabetes Res Clin Pract 1997, 34:169-179.
70. Stamboulis E., Vassilopoulos D., Kalfakis N. Symptomatic focal mononeuropathies in diabetic patients: increased or not?. J Neurol 2005, 252:448-452.
71. Stewart J.D. Diabetic truncal neuropathy: topography of the sensory deficit. Ann Neurol 1989, 25:233-238.
72. Sugimoto K., Yasujima M., Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008, 14:953-961.
73. Sumner C., Sheth S., Griffin J., et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003, 60:108-111.
74. Tavakoli M., Quattrini C., Abbot D. Corneal confocal microscopy. A novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 2010, 22:1792-1797.
75. Tesfaye S., Chaturvedi N., Eaton S., et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341-350.
76. Thornalley P. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 2002, 50:37-57.
77. Tomlinson D. Mitogen-activated protein kinase C as glucose transducers for diabetic complications. Diabetologia 1999, 42:1271-1281.
78. UK Prospective Diabetes Study Group (UKPDS) XI. Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 1994, 11:534-544.
79. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
80. Van Etten R., deKoning F., Verhaar M., et al. NO-dependent vasodilation in patients with type II non-insulin-dependent diabetes mellitus is restored by acute administration of folate. Diabetologia 2002, 45:1004-1010.
81. Verhaar M., Stroes E., Rabelink T. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 2002, 22:6-11.
82. Vincent A., Russell J., Low P., et al. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004, 25:612-628.
83. Vinik A.I., Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007, 115:387-397.
84. Vinik A., Maser R., Mitchell B., et al. Diabetic autonomic neuropathy. Diabetes Care 2003, 26:1553-1579.
85. Vinik A., Bril V., Kempler P., et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 2005, 27:1164-1180.
86. Walker M., Morris L., Cheng D. Improvement of cutaneous sensitivity in diabetic peripheral neuropathy with combination L-methylfolate, methylcobalamin and pyridoxal 5-phosphate. Rev Neurol Dis 2010, 7:132-139.
87. Wile D., Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010, 33:156-161.
88. Wright R., Kaufmann H., Perera R., et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998, 51:120-124.
89. Zhang W., Wan Po A. The effectiveness of topically applied capsaicin: a meta analysis. Eur J Clin Pharmacol 1994, 45:517-522.
90. Zhong X., Zheng B., Hu G., et al. Peripheral and autonomic nerve function tests in early diagnosis of diabetic neuropathy: correlation between motor nerve conduction velocity and fasting plasma glucose. Chin Med J (Engl) 1981, 94:495-502.
91. Ziegler D., Gries F., Spuler M., et al. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications 1992, 6:49-57.
92. Ziegler D., Hanefeld M., Ruhnau K., et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid. A three-week multicentre randomized controlled trial (ALADIN study). Diabetologia 1995, 38:1425-1433.
93. Ziegler D., Hanefeld M., Ruhnau K. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). Diabetes Care 1999, 22:1296-1301.
94. Ziegler D., Nowak H., Kempler P. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta analysis. Diabet Med 2004, 21:114-121.
95. Ziegler D., Ametov A., Barinov A., et al. Oral treatment with alpha lipoic acid improves symptomatic diabetic polyneuropathy-the SYDNEY 2 trial. Diabetes Care 2006, 29:2365-2370.
96. Ziegler D., Rathmann W., Dickhaus T., et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg surveys S2 and S3. Diabetes Care 2008, 31:464-469.
97. Ziegler D., Hidvegi T., Gurieva I., et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010, 33:838-841.
98. Ziegler D., Low P., Litchy W., et al. Efficacy and safety of antioxidant treatment with alpha lipoic acid over 4 years in diabetic polyneuropathy. The NATHAN 1 trial. Diabetes Care 2011, 34:2054-2060.